Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Cell Therapeutics, Inc. (CTI) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone).
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.
Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.
Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.
Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.
Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).
It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex environment of the body.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
MRI scans of children who have had chemotherapy can detect early changes in their hearts finds research in biomed Central's open access journal Journal of Cardiovascular Magnetic Resonance.
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology.
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.